Working… Menu
Trial record 71 of 106 for:    "Kennedy disease"

11C or 18F-Choline PET/CT and Whole Body MRI for Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02815033
Recruitment Status : Active, not recruiting
First Posted : June 28, 2016
Last Update Posted : August 15, 2019
Centre for Human Drug Research, Netherlands
Information provided by (Responsible Party):
The European Uro-Oncology Group

Brief Summary:

The aim of the study is to assess the clinical utility of 11C or 18F-Choline Positron Emission Tomography (PET)/Computed Tomography (CT) scan, Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and prostate-specific antigen (PSA) measurements in response prediction to treatment with Enzalutamide in Hormono-Sensitive Metastatic Prostate Cancer patients.

The study will assess how these 2 imaging modalities perform compared to traditional serial PSA measurements and bone scan in assessing metastatic tumour load, progressive disease and response to treatment with Enzalutamide.

In addition measurements of serially collected circulating tumour cell (CTC) samples, cell-free tumour DNA and RNA will be performed in order to evaluate their predictive value in terms of response measurement.

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastatic Drug: Enzalutamide Procedure: 11C or 18F-Choline PET/CT Procedure: Whole body MRI Procedure: Bone scan Phase 2

Detailed Description:
Metastatic prostate cancer patients eligible for 1st line hormonal treatment will undergo treatment with Enzalutamide (XTANDI). Subjects will receive 1dd 160 mg Enzalutamide orally continuously until progressive disease occurs. All subjects will undergo Choline (11C or 18F)-PET/CT scans at baseline, 2 weeks, 2 and 6, 9 and 12 months after starting androgen receptor (AR)-directed treatment. All subjects will undergo Whole Body MRI at baseline, 6, 9 and 12 months. Bone scans will be performed at baseline, 3 months, 6 and 12 months. PSA will be measured at baseline and every 4 weeks thereafter until at 12 months. CTC counts and characteristics will be measured at baseline and during Enzalutamide treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)
Study Start Date : July 2015
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Single arm
Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
Drug: Enzalutamide
Procedure: 11C or 18F-Choline PET/CT
Procedure: Whole body MRI
Procedure: Bone scan

Primary Outcome Measures :
  1. Progression-Free Survival (PFS) at 6 and 12 months. [ Time Frame: 6 and 12 months ]

    Radiological progression is defined by any of the following criteria:

    • Soft tissue lesions: Progressive disease on Choline (11C or 18F) PET/CT or Whole Body MRI by RECIST 1.1. Bone or bone marrow lesions: Progressive disease on PET/CT or MRI as evidenced by new lesions or an increase in size of 25% of the sum of target lesions.
    • Conversion of the Choline (11C or 18F) PET signal of the metastases at 2 weeks, 2 or 6 months compared to baseline PET which by comparing it to PFS at 6 and 12 months may be an indicator or drug response. Radiological PFS at 6 and 12 months will be compared to a) PET signal conversion and to b) PSA measurements, and changes in number of lesions on the bone scan (conventional work up).

Secondary Outcome Measures :
  1. Biochemical response defined as prostate-specific antigen (PSA) nadir [ Time Frame: 12 months ]
  2. PSA progression. PSA kinetics measured by PSA doubling time (regular PSA measurements) [ Time Frame: 12 months ]
  3. Progression of bone lesions detected with bone scan according to Prostate Cancer Working Group 2 (PCWG2) criteria [ Time Frame: 6 and 12 months ]
  4. Radiologically confirmed spinal cord compression or pathological fracture due to malignant progression [ Time Frame: 6 and 12 months ]
  5. Occurrence of Symptomatic Skeletal Events (SSE) evaluated by combination of clinical and radiological assessments [ Time Frame: 12 months ]
    SSE is defined as external beam radiation therapy to relieve skeletal pain, occurrence of a new symptomatic pathologic bone fracture, spinal cord compression, tumour-related orthopedic surgical intervention or change of anti-neoplastic therapy to treat bone pain

  6. Circulating tumour cell (CTC) measurements and comparison with radiological PFS at 6 and 12 months [ Time Frame: 6 and 12 months ]
  7. Percent change from baseline in serum concentration of circulating testosterone (T) [ Time Frame: 12 months ]
  8. Percent change from baseline in serum concentration of dihydrotestosterone (DHT) [ Time Frame: 12 months ]
  9. Percent change from baseline in serum concentration of sex hormone binding globulin (SHBG) [ Time Frame: 12 months ]
  10. Percent change from baseline in serum concentration of androstenedione (A) [ Time Frame: 12 months ]
  11. Number of participants with changes in biomarkers of bone turnover correlated to PSA [ Time Frame: 12 months ]
  12. Number of participants with adverse events (AEs) and serious adverse events (SAEs) leading to treatment discontinuation [ Time Frame: 6 and 12 months ]
  13. Time to symptomatic progression (including death due to prostate cancer) [ Time Frame: 12 months ]
  14. Time to first radiological or symptomatic progression [ Time Frame: 6 and 12 months ]
  15. Time to initiation of salvage systemic therapy, including chemotherapy, or palliative radiation [ Time Frame: 12 months ]
  16. Quality of life measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [ Time Frame: 6 and 12 months ]
  17. Quality of life measured by the EuroQol 5-Dimension QoL Instrument (EQ-5D) [ Time Frame: 6 and 12 months ]
  18. Changes in Sexual Function (IIEF) [ Time Frame: 6 and 12 months ]
  19. Changes in Karnofsky score [ Time Frame: 6 and 12 months ]
  20. Changes in visual analogue scale (VAS) for tumour-related pain [ Time Frame: 6 and 12 months ]
  21. Changes in bone mineral density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA) scan [ Time Frame: 6 and 12 months ]
  22. Early Health Technology Assessment to calculate cost-effectiveness of both diagnostic procedures [ Time Frame: 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male aged 18 years or older;
  • Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features;
  • Three consecutive rises of PSA, 1 week apart, resulting in two 50% increases over the nadir, with PSA of at least > 2 ng/mL but preferably >20 ng/mL;
  • Progressive disease defined by rising PSA levels plus by evidence of progressive and measurable soft tissue or bone disease by 11C or 18F-Choline PET/CT, Whole Body MRI or both;
  • No prior treatment with cytotoxic chemotherapy;
  • Eastern Cooperative Oncology Group (ECOG) score 0-2;
  • A life expectancy of at least 12 months;
  • Written informed consent;

Exclusion Criteria:

  • Treatment with androgen deprivation therapy with a gonadotropin-releasing hormone analogue, luteinizing hormone-releasing hormone antagonist, or bilateral orchiectomy within 6 months of enrolment (Day1 visit);
  • Treatment with anti-androgens such as bicalutamide, nilutamide or flutamide within 6 weeks of enrolment (Day 1 visit);
  • Treatment with 5-α reductase inhibitors (finasteride, dutasteride), estrogens, cyproterone acetate within 4 weeks of enrolment (Day 1 visit);
  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrolment;
  • Known or suspected brain metastasis or active leptomeningeal disease;
  • History of another malignancy within the previous 5 years other than curatively treated non melanomatous skin cancer;
  • Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times the upper limit of normal at the Screening visit;
  • Creatinine > 177 µmol/L (2 mg/dL) at the Screening visit;
  • Hemoglobin <6 mmol/L, White blood cells < 4.0 x 10^9/L, Platelets < 100 x 10^9/L;
  • History of seizure or any condition that may predispose to seizure. Also, history of loss of consciousness or transient ischemic attack within 12 months of enrolment (Day 1 visit);
  • Contra-indication for MRI (e.g. pacemaker).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02815033

Layout table for location information
Leiden University Medical Center
Leiden, Netherlands, 2333 ZA
Sponsors and Collaborators
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands
Layout table for investigator information
Study Chair: Susanne Osanto, MD PhD The European Uro-Oncology Group (EUOG)

Additional Information:
Layout table for additonal information
Responsible Party: The European Uro-Oncology Group Identifier: NCT02815033     History of Changes
Other Study ID Numbers: EudraCT Number: 2014-001162-10
First Posted: June 28, 2016    Key Record Dates
Last Update Posted: August 15, 2019
Last Verified: August 2019
Keywords provided by The European Uro-Oncology Group:
Hormono-Sensitive prostate cancer
Whole body MRI
Circulating tumour cells
Cell-free tumour DNA
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Immune System Diseases
Lipotropic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Lipid Regulating Agents
Nootropic Agents